Founded in 1945, PROCOS S.p.A. is a historical player in the pharmaceutical industry, with a long-standing reputation for excellence in the development, scale-up, and manufacturing of small molecule APIs. As the company celebrates its 80th anniversary in 2025, it continues to reinforce its position as a trusted CDMO partner, recognized for its deep expertise in custom manufacturing and its commitment to high-quality production standards.
While PROCOS more recently expanded into the highly potent (HPAPI) space, its core strength remains the synthesis of non-HP small molecules—a domain in which it has built a rich legacy of innovation and industrial reliability since the early 2000’s. This legacy forms the foundation of the company’s newest strategic investment: the completion of a new production department titled R11.
R11 is a multipurpose manufacturing building designed to meet the growing demand for complex small molecules. The four-floor building spans approximately 4,000 m² and houses up to four production lines equipped with commercial scale reactors (1,000 L to 6,000 L), centrifuges, and advanced drying systems, which will support small to mid-size clinical or market volume needs.
The Phase I investment, totaling over €60 million, delivers around 75 cubic meters of new cGMP manufacturing capacity. The facility is tailored to support clinical supply across phases I to III, , addressing a wide range of customer needs in pharmaceutical development, as well as commercial manufacturing.
The equipment installation is complete, and the regulatory qualification is now underway, with cGMP production expected to start by early 2026. The planned Phase II investment will further increase scale and flexibility, adding up to 15 reactors and expanding drying capabilities. Together, R11’s two phases are projected to increase overall site capacity by approximately 25 (percent), enabling future production at PROCOS’ site to exceed 350 metric tons of APIs per year.
“This investment is a milestone in our journey,” said Enrico Zodio, CEO of PROCOS. “R11 embodies our long-term vision to grow organically while supporting the evolving needs of our partners. It reinforces our leadership in small molecule manufacturing, including for high-value and rare disease therapies.”
